Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Chlamydia pneumoniae inhibits activated human T lymphocyte proliferation by the induction of apoptotic and pyroptotic pathways.

Olivares-Zavaleta N, Carmody A, Messer R, Whitmire WM, Caldwell HD.

J Immunol. 2011 Jun 15;186(12):7120-6. doi: 10.4049/jimmunol.1100393. Epub 2011 May 4.

2.

The sst1 resistance locus regulates evasion of type I interferon signaling by Chlamydia pneumoniae as a disease tolerance mechanism.

He X, Berland R, Mekasha S, Christensen TG, Alroy J, Kramnik I, Ingalls RR.

PLoS Pathog. 2013;9(8):e1003569. doi: 10.1371/journal.ppat.1003569. Epub 2013 Aug 29.

3.

Chlamydia pneumoniae as a respiratory pathogen.

Hahn DL, Azenabor AA, Beatty WL, Byrne GI.

Front Biosci. 2002 Mar 1;7:e66-76. Review.

PMID:
11861211
4.

Chlamydia pneumoniae modulates human monocyte-derived dendritic cells functions driving the induction of a Type 1/Type 17 inflammatory response.

Flego D, Bianco M, Quattrini A, Mancini F, Carollo M, Schiavoni I, Ciervo A, Ausiello CM, Fedele G.

Microbes Infect. 2013 Feb;15(2):105-14. doi: 10.1016/j.micinf.2012.11.004. Epub 2012 Nov 16.

PMID:
23164610
5.

Deficiency of XIAP leads to sensitization for Chlamydophila pneumoniae pulmonary infection and dysregulation of innate immune response in mice.

Prakash H, Albrecht M, Becker D, Kuhlmann T, Rudel T.

J Biol Chem. 2010 Jun 25;285(26):20291-302. doi: 10.1074/jbc.M109.096297. Epub 2010 Apr 28.

6.

Divergent modulation of Chlamydia pneumoniae infection cycle in human monocytic and endothelial cells by iron, tryptophan availability and interferon gamma.

Bellmann-Weiler R, Martinz V, Kurz K, Engl S, Feistritzer C, Fuchs D, Rupp J, Paldanius M, Weiss G.

Immunobiology. 2010 Sep-Oct;215(9-10):842-8. doi: 10.1016/j.imbio.2010.05.021. Epub 2010 Jun 4.

PMID:
20646782
7.

Chlamydophila pneumoniae infection leads to smooth muscle cell proliferation and thickening in the coronary artery without contributions from a host immune response.

Deniset JF, Cheung PK, Dibrov E, Lee K, Steigerwald S, Pierce GN.

Am J Pathol. 2010 Feb;176(2):1028-37. doi: 10.2353/ajpath.2010.090645. Epub 2009 Dec 17.

8.

Detection of Chlamydia pneumoniae but not of Helicobacter pylori in symptomatic atherosclerotic carotids associated with enhanced serum antibodies, inflammation and apoptosis rate.

Neureiter D, Heuschmann P, Stintzing S, Kolominsky-Rabas P, Barbera L, Jung A, Ocker M, Maass M, Faller G, Kirchner T.

Atherosclerosis. 2003 May;168(1):153-62.

PMID:
12732399
9.

Chlamydia pneumoniae induces T cell apoptosis through glutathione redox imbalance and secretion of TNF-alpha.

Sessa R, Di Pietro M, Schiavoni G, Macone A, Maras B, Fontana M, Zagaglia C, Nicoletti M, Del Piano M, Morrone S.

Int J Immunopathol Pharmacol. 2009 Jul-Sep;22(3):659-68.

PMID:
19822082
10.

Multiple Chlamydia pneumoniae antigens prime CD8+ Tc1 responses that inhibit intracellular growth of this vacuolar pathogen.

Wizel B, Starcher BC, Samten B, Chroneos Z, Barnes PF, Dzuris J, Higashimoto Y, Appella E, Sette A.

J Immunol. 2002 Sep 1;169(5):2524-35.

11.

Molecular pathogenesis of chronic Chlamydia pneumoniae infection: a brief overview.

Kern JM, Maass V, Maass M.

Clin Microbiol Infect. 2009 Jan;15(1):36-41. doi: 10.1111/j.1469-0691.2008.02631.x. Review.

12.

Temporal delay of peak T-cell immunity determines Chlamydia pneumoniae pulmonary disease in mice.

Wang C, van Ginkel FW, Kim T, Li D, Li Y, Dennis JC, Kaltenboeck B.

Infect Immun. 2008 Nov;76(11):4913-23. doi: 10.1128/IAI.00569-08. Epub 2008 Aug 25.

13.

Chlamydia pneumoniae infection suppresses Staphylococcus enterotoxin B-induced proliferation associated with down-expression of CD25 in lymphocytes.

Hirai I, Utsumi M, Yamaguchi H, Yamamoto Y.

Can J Microbiol. 2010 Apr;56(4):289-94. doi: 10.1139/w10-018.

PMID:
20453895
14.

Chlamydia pneumoniae infects and multiplies in lymphocytes in vitro.

Haranaga S, Yamaguchi H, Friedman H, Izumi S, Yamamoto Y.

Infect Immun. 2001 Dec;69(12):7753-9.

15.

Restriction of Chlamydia pneumoniae replication in human dendritic cell by activation of indoleamine 2,3-dioxygenase.

Njau F, Geffers R, Thalmann J, Haller H, Wagner AD.

Microbes Infect. 2009 Nov;11(13):1002-10. doi: 10.1016/j.micinf.2009.07.006. Epub 2009 Jul 28.

PMID:
19643200
16.

Chlamydia pneumoniae and chronic skin wounds: a focused review.

King LE Jr, Stratton CW, Mitchell WM.

J Investig Dermatol Symp Proc. 2001 Dec;6(3):233-7. Review.

17.

Unstable atherosclerotic plaques contain T-cells that respond to Chlamydia pneumoniae.

de Boer OJ, van der Wal AC, Houtkamp MA, Ossewaarde JM, Teeling P, Becker AE.

Cardiovasc Res. 2000 Dec;48(3):402-8.

PMID:
11090835
18.

Chlamydia pneumoniae-induced pathological signaling in the vasculature.

Kern JM, Maass V, Maass M.

FEMS Immunol Med Microbiol. 2009 Mar;55(2):131-9. doi: 10.1111/j.1574-695X.2008.00514.x. Review.

19.

Inflammation and fibrosis during Chlamydia pneumoniae infection is regulated by IL-1 and the NLRP3/ASC inflammasome.

He X, Mekasha S, Mavrogiorgos N, Fitzgerald KA, Lien E, Ingalls RR.

J Immunol. 2010 May 15;184(10):5743-54. doi: 10.4049/jimmunol.0903937. Epub 2010 Apr 14.

20.

Cell mediated immunity to Chlamydia pneumoniae.

Halme S, Surcel HM.

Scand J Infect Dis Suppl. 1997;104:18-21. Review.

PMID:
9259075

Supplemental Content

Support Center